An Evaluation of Inpatient Treatment Continuation and Hospital Readmission Rates in Patients with Bipolar Disorder Treated with Aripiprazole or Quetiapine

Abstract

No difference was observed in inpatient antipsychotic treatment continuation and 30-day hospital readmission rates in patients treated with either aripiprazole or quetiapine.

Predictors of psychiatric readmission among patients with bipolar disorder at an academic safety-net hospital

“…In the present study, patient race/ethnicity was not found to predict readmission across the time periods examined. This finding is consistent with previous research that found no relationship between race/ethnicity and psychiatric readmission (Appleby et al, 1993;Kreys et al, 2013;Schmutte et al, 2010).…”

“…Among studies that included patients with schizophrenia and/or affective disorders (Appleby et al, 1993; Monnely, 1997; Swett, 1995) as well as studies that only included patients with BD (Kessing et al, 2004; Kreys et al, 2013; Patel et al, 2005), a greater number of prior psychiatric hospitalizations was found to increase the risk of readmission.…”

“…A few studies have examined risk factors for readmission in samples that included only patients with BD (Kessing et al, 2004; Kreys et al, 2013; Patel et al, 2005; Perlick et al, 1999; Woo et al, 2014). In addition to the impact of the number of BD episodes on psychiatric readmission as reported above (Kessing et al, 2004), one prospective study examined the effect of clinical symptoms as risk factors for psychiatric readmission among 100 patients with BD (Perlick et al, 1999), and three studies examined the effect of medication differences on psychiatric readmission among patients with BD (Kreys et al, 2013; Patel et al, 2005; Woo et al, 2014). Two studies examining the effects of medication differences on psychiatric readmission for patients with BD found no relationship between medication differences and psychiatric readmission; however, both studies found a greater number of prior psychiatric hospitalizations increased readmission risk (Kreys et al, 2013; Patel et al, 2005).…”

Pre-discharge factors predicting readmissions of psychiatric patients: a systematic review of the literature

“…Some studies focused on at least one substance use disorder (alcohol dependence, alcohol abuse, alcoholic psychosis, drug dependence, drug abuse, drug psychosis) or inpatients in a substance abuse treatment program with a main alcohol/drug diagnosis or dual diagnosis patients [15, 21–24, 32]. Five studies were restricted to diagnosis of schizophrenia or schizoaffective disorders or psychosis [33–37]; four to diagnosis of affective disorder [19, 26, 38, 39]; two to diagnosis of dementia [18, 40]. …”

“…Six papers [17, 28, 35, 39, 48, 66] analysed different aspects of pharmacological treatment (such as dosage or medication prescription), but it resulted significant in only the three of them discussed below and always in bivariate associations. Being on depot injectable antipsychotic medication turned out as a risk factor, while using atypical antipsychotic medication was protective towards readmission [66].…”